

To:	Public Trust Board
From:	Jan Sobieraj, Chief Executive
Date:	7 January 2019

Title:	Position Statement on EU Exit Preparations						
Author/Responsible Director: Jan Sobieraj, Chief Executive							
Purpose of the Report: To update the Trust Board on actions taken in preparation for EU Exit following the latest guidance from Secretary of State for Health.							
The Report is provided to the Board for:							
<table border="1"> <tr> <td>Information</td> <td>X</td> </tr> </table>		Information	X	<table border="1"> <tr> <td>Assurance</td> <td>X</td> </tr> </table>		Assurance	X
Information	X						
Assurance	X						
<table border="1"> <tr> <td>Discussion</td> <td></td> </tr> </table>		Discussion		<table border="1"> <tr> <td>Decision</td> <td></td> </tr> </table>		Decision	
Discussion							
Decision							
Summary/Key Points:							
<ul style="list-style-type: none"> • Latest guidance was received from Secretary of State for Health on 7 December 2018 (copy attached as appendix 1) • Actions taken in response to guidance are detailed • Trust SRO for EU Exit planning is the Deputy Chief Executive. 							
Recommendations: To note.							
Strategic Risk Register Review latest position to confirm adequacy of risk register entries		Performance KPIs year to date N/A					
Resource Implications (eg Financial, HR) Within budgets							
Assurance Implications N/A							
Patient and Public Involvement (PPI) Implications N/A							
Equality Impact Staff employed from within EU have been identified and are being supported.							
Information exempt from Disclosure N/A							
Requirement for further review? Trust Board to be updated							

Summary

The Secretary of State for Health and Social Care has issued further guidance for health and social care organisations. The guidance includes a number of recommendations for actions which should be taken by Trusts as a safeguard as we move towards the exit from the EU on the 29 March 2019.

This report provides an update to the Trust Board on local actions which have been taken in 2018 and in response to the latest guidance.

In general terms Trusts are being advised that there is no need to stockpile medicines, medical devices or clinical consumables. Clinicians should not be writing longer NHS prescriptions and should advise their patients that there is no necessity to store additional medication at home.

Recommendations

Supply of non clinical consumables, goods and services - Trusts were advised in October that nationally a review was underway of all national supplier contracts for the NHS. The additional step which Trusts were asked to take locally was that they assess their remaining supply chain contracts (outside the categories of the national suppliers) for non-clinical goods and services using a self -assessment template and return the results to the Department of Health and Social Care

• Action taken by Trust

- Procurement have engaged with the DHSC EU Exit Planning team. The Trust completed the contract review of 3rd party spend against the NHS Self-Assessment Methodology (spend data provided by the central EU planning team) and submitted a return detailing any contracts felt to be higher risk to the provision of healthcare services at 29th March 2019 by November 30th 2018, as required.
- The central EU Exit Planning team are covering a number of areas, so that Trust don't have to. These include medical devices and clinical consumables (all products purchased via NHSSC), licensed medicines and vaccines, food, nutritional feeds, Pathology/in vitro diagnostic (IVD) devices, capital equipment and spare parts, hotel services (e.g. laundry) and other major suppliers to the NHS (originally 800+ listed) The central teams list continues to grow as Trusts identify common areas.
- The Procurement Team reviewed the spend data from DHSC by category concentrating on values over £25k and for products/services that may directly affect patient care. The outcome of this was only a handful of suppliers identified that did not fall under the DHSC remit to check and statements have been requested from these suppliers on their preparedness for EU no deal exit.

Workforce – It was suggested that Trusts should consider meeting the cost of registration for EU settled status for members of its workforce. Organisations were asked to promote the scheme to EU nationals which has been opened to allow for early registration from health and social care staff.

- **Action taken by Trust**

- The Trust considered and have agreed to meet the costs of registration for EU settled status
- The Trust has written to all employed EU nationals and promoted the scheme for early registration

Clinical Trials – Organisations were advised to take action to understand the supply chains for all clinical trials or investigations to ensure arrangements for continuity of supply

- **Action taken by Trust**

- Director of Research and Development has confirmed that the Trust is not currently the sponsor of any drug trials, the supply of drugs is the responsibility of the sponsor, however the Trust is running a number of trials with sponsors based in the UK. The Trust is contacting each of these organisations to confirm that they have appropriate plans in place.

Business Continuity Planning – Organisations have been advised that they should continue to update business continuity plans for the possibility of a no deal EU exit and organisations should contribute to their Local Resilience Forums assessments and preparations.

- **Action taken by Trust**

- The Emergency Planning Team have confirmed their engagement with the LRF who on the back of the 7 December guidance are setting up Brexit contingency meetings between now and March 2019
- The Trust is taking account of national and local advice and an initial brexit business continuity plan will be produced in January 2019

Next steps

The Trust will continue to review and respond to all guidance issued.

Updates will be provided to the Trust Board.